Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trial

The oral KRAS G12D inhibitor GFH375 achieved an objective response in 57.7% (90% CI: 39.8–74.2%) of previously treated NSCLC patients with KRAS G12D mutations (n=28), rising to 68.8% (n=16) at the 600 mg once-daily dose level. Six-month progression-free survival was 60.4–77.4% depending on dose. Grade ≥3 treatment-related adverse events occurred in 37.2% of 86 phase 1 participants; one treatment-related death was reported (1.2%).